EP2029743A4 - Méthodes pour le diagnostic et le traitement de complications associées à une grossesse - Google Patents

Méthodes pour le diagnostic et le traitement de complications associées à une grossesse

Info

Publication number: EP2029743A4
Authority: EP; European Patent Office
Prior art keywords: diagnosis; treatment; pregnancy complications; pregnancy; complications
Prior art date: 2006-05-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP07795515A

Other languages

German (de)

English (en)

Other versions

EP2029743A1 (fr

Inventor

S Ananth Karumanchi

Vikas P Sukhatme

Mourad Toporsian

Michelle V Letarte

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Hospital for Sick Children HSC

Beth Israel Deaconess Medical Center Inc

Original Assignee

Hospital for Sick Children HSC

Beth Israel Deaconess Medical Center Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-31

Filing date

2007-05-31

Publication date

2010-12-08

2006-05-31 Priority claimed from US11/443,920 external-priority patent/US7740849B2/en

2007-05-31 Application filed by Hospital for Sick Children HSC, Beth Israel Deaconess Medical Center Inc filed Critical Hospital for Sick Children HSC

2009-03-04 Publication of EP2029743A1 publication Critical patent/EP2029743A1/fr

2010-12-08 Publication of EP2029743A4 publication Critical patent/EP2029743A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1841—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1858—Platelet-derived growth factor [PDGF]
- A61K38/1866—Vascular endothelial growth factor [VEGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/486—Elastase (3.4.21.36 or 3.4.21.37)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/36—Gynecology or obstetrics
- G01N2800/368—Pregnancy complicated by disease or abnormalities of pregnancy, e.g. preeclampsia, preterm labour

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Physics & Mathematics (AREA)
Orthopedic Medicine & Surgery (AREA)
Cardiology (AREA)
Mycology (AREA)
Heart & Thoracic Surgery (AREA)
Reproductive Health (AREA)
Cell Biology (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Food Science & Technology (AREA)
Vascular Medicine (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)

EP07795515A 2006-05-31 2007-05-31 Méthodes pour le diagnostic et le traitement de complications associées à une grossesse Withdrawn EP2029743A4 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US11/443,920 US7740849B2 (en)	2004-09-24	2006-05-31	Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
US85276106P	2006-10-19	2006-10-19
PCT/US2007/012787 WO2008030283A1 (fr)	2006-05-31	2007-05-31	Méthodes pour le diagnostic et le traitement de complications associées à une grossesse

Publications (2)

Publication Number	Publication Date
EP2029743A1 EP2029743A1 (fr)	2009-03-04
EP2029743A4 true EP2029743A4 (fr)	2010-12-08

Family

ID=39157545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP07795515A Withdrawn EP2029743A4 (fr)	2006-05-31	2007-05-31	Méthodes pour le diagnostic et le traitement de complications associées à une grossesse

Country Status (9)

Country	Link
EP (1)	EP2029743A4 (fr)
JP (1)	JP2009538915A (fr)
KR (1)	KR20090040874A (fr)
CN (1)	CN101517078A (fr)
AU (1)	AU2007293475A1 (fr)
BR (1)	BRPI0713122A2 (fr)
CA (1)	CA2654283A1 (fr)
MX (1)	MX2008015197A (fr)
WO (1)	WO2008030283A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7740849B2 (en)	2004-09-24	2010-06-22	Beth Israel Deaconess Medical Center	Use of compounds that bind soluble endoglin and SFLT-1 for the treatment of pregnancy related hypertensive disorders
EP2347765B1 (fr)	2004-09-24	2014-01-22	Beth Israel Deaconess Medical Center	Méthodes pour le diagnostic et le traitement de complications associées à une grossesse
EP1839057B1 (fr)	2004-12-15	2010-08-25	Beth Israel Deaconess Medical Center	Acides nucleiques et polypeptides utiles pour diagnostiquer et traiter des complications de la grossesse
WO2009097584A1 (fr) *	2008-01-30	2009-08-06	Proteogenix, Inc.	Biomarqueurs de sérum maternel pour la détection de pré-éclampsie
MX2010014228A (es) *	2008-06-18	2011-03-29	Abbott Laboratories Star	Metodos y productos de diagnostico del p/gf-1 acompañante.
CN104749384B (zh) *	2009-04-23	2017-04-12	沃莱克公司	确定母体健康风险的方法
WO2011116958A1 (fr) *	2010-03-24	2011-09-29	Preelumina Diagnostics Ab	Hbf et a1m à titre de marqueurs précoces de prééclampsie
US20110251094A1 (en)	2010-04-13	2011-10-13	Pronota N.V.	Biomarkers for hypertensive disorders of pregnancy
AU2011240039B2 (en) *	2010-04-13	2017-01-19	Mycartis Nv	Biomarkers for hypertensive disorders of pregnancy
EP2569253A4 (fr)	2010-05-14	2013-10-02	Beth Israel Hospital	Dispositifs extracorporels et procédés de traitement de complications de grossesse
CN102058435B (zh) *	2011-01-17	2012-05-09	北京工业大学	基于理化和血流动力学信息的妊娠期高血压风险监测装置
EP2726631A1 (fr)	2011-06-28	2014-05-07	Vitateq Biotechnology GmbH	Procédé pour le diagnostic de pré-éclampsie
JP2014524417A (ja) *	2011-08-01	2014-09-22	タフツメディカルセンターインコーポレイテッド	心不全および関連状態の処置
US20140141456A1 (en) *	2012-08-30	2014-05-22	Ansh Labs, LLC	Papp-a2 as a marker for monitoring, predicting and diagnosing preeclampsia
KR101417379B1 (ko) *	2012-10-30	2014-07-10	곽호석	질량분석기를 이용한 태아의 폐 성숙도 진단방법
CN103235142B (zh) *	2013-04-28	2015-04-15	成都中医药大学	一种孕妇初次妊娠筛查试剂盒
CN103207274B (zh) *	2013-04-28	2015-02-25	成都中医药大学	一种胎儿7号染色体异常疾病的筛查试剂盒
WO2017173260A1 (fr) *	2016-03-31	2017-10-05	ImMutriX Therapeutics, Inc.	Procédé de traitement extracorporel de la prééclampsie et de troubles associés
EP3446123A4 (fr) *	2016-04-20	2019-11-06	LDX Prognostics Limited Co.	Procédés et compositions pour pronostiquer une naissance prématurée
MX2022001020A (es) *	2019-07-29	2022-04-06	Univ Illinois	Composicion y metodo para promover la cicatrizacion de heridas.
CN113919453B (zh) *	2021-09-13	2024-06-11	深圳大学龙华生物产业创新研究院	用于记录生物特征的区块链集成系统
CN113933129B (zh) *	2021-09-14	2024-01-12	深圳大学	子痫前期诊断试剂盒以及荧光染料的应用
CN115791340B (zh) *	2023-01-17	2023-05-02	北京水木济衡生物技术有限公司	一种子痫复合质控品及其制备方法和应用
CN118340868A (zh) *	2024-05-11	2024-07-16	山东大学	骨形态发生蛋白7在子痫前期预防和/或治疗中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006034507A2 (fr) *	2004-09-24	2006-03-30	Beth Israel - Deaconess Medical Center	Methodes de diagnostic et de traitement lors de complications de la grossesse

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020031513A1 (en) *	1997-11-24	2002-03-14	Shamir Leibovitz	Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
SK14692001A3 (sk) *	1999-04-16	2002-09-10	Yale University	Izolovaná molekula nukleovej kyseliny, izolovaný NOS polypeptid, spôsob stimulácie, spôsob liečby, spôsob identifikácie a nehumánne transgénne zviera
US20050043227A1 (en) *	2001-04-24	2005-02-24	Veerle Compernolle	Use of hypoxia inducible factor 2alpha for curing neonatal respiratory distress syndrome and as a target for the treatment of pulmonary hypertension

2007
- 2007-05-31 EP EP07795515A patent/EP2029743A4/fr not_active Withdrawn
- 2007-05-31 KR KR1020087032270A patent/KR20090040874A/ko not_active Ceased
- 2007-05-31 CA CA002654283A patent/CA2654283A1/fr not_active Abandoned
- 2007-05-31 CN CNA2007800268583A patent/CN101517078A/zh active Pending
- 2007-05-31 JP JP2009513263A patent/JP2009538915A/ja active Pending
- 2007-05-31 WO PCT/US2007/012787 patent/WO2008030283A1/fr not_active Ceased
- 2007-05-31 BR BRPI0713122-4A patent/BRPI0713122A2/pt not_active IP Right Cessation
- 2007-05-31 MX MX2008015197A patent/MX2008015197A/es active IP Right Grant
- 2007-05-31 AU AU2007293475A patent/AU2007293475A1/en not_active Abandoned

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006034507A2 (fr) *	2004-09-24	2006-03-30	Beth Israel - Deaconess Medical Center	Methodes de diagnostic et de traitement lors de complications de la grossesse

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2008030283A1 *

Also Published As

Publication number	Publication date
WO2008030283A1 (fr)	2008-03-13
CA2654283A1 (fr)	2008-03-13
CN101517078A (zh)	2009-08-26
BRPI0713122A2 (pt)	2012-04-17
KR20090040874A (ko)	2009-04-27
AU2007293475A1 (en)	2008-03-13
EP2029743A1 (fr)	2009-03-04
MX2008015197A (es)	2009-06-23
JP2009538915A (ja)	2009-11-12

Publication	Publication Date	Title
EP2029743A4 (fr)	2010-12-08	Méthodes pour le diagnostic et le traitement de complications associées à une grossesse
EP2041317A4 (fr)	2009-10-14	Procédés et compositions à base de micro-arn pour le diagnostic et le traitement de maladies apparentées au cancer du colon
EP1991274A4 (fr)	2009-06-10	Méthode de traitement, de prophylaxie et de diagnostic de pathologies osseuses
EP2306814A4 (fr)	2011-08-31	Procédés pour le diagnostic et le traitement d'une cardiopathie chez un patient
ATE489955T1 (de)	2010-12-15	Verfahren und zusammensetzung zur behandlung von peripheren gefässkrankheiten
EP2370593A4 (fr)	2012-09-05	Procédés pour le traitement d'infections et de tumeurs
EP2127728A4 (fr)	2011-09-21	Procédé et appareil destinés au traitement de gaz de décharge
EP1881823A4 (fr)	2009-06-17	Compositions et procedes pour le traitement des troubles oculaires
EP1945754A4 (fr)	2009-06-24	Compositions et méthodes pour traiter et diagnostiquer un cancer
DE602004014095D1 (de)	2008-07-10	Verfahren und Gerät zur nichtinvasiven Diagnostik-Bilderzeugung
EP2054047A4 (fr)	2012-05-23	Procédé de traitement de traumatisme acoustique aigu
EP2068710A4 (fr)	2009-10-21	Appareil et procédé de traitement d'une apnée du sommeil obstruante
DE602007001291D1 (de)	2009-07-30	Vorrichtung zur Behandlung eines Blutschlauchs und Verfahren zur Herstellung dieser Vorrichtung
EP1981491A4 (fr)	2009-09-23	Compositions et procedes de traitement de la secheresse ophtalmique
EP1896083A4 (fr)	2009-09-30	Méthode pour traiter la maladie de pompe au moyen de 1-désoxynojirimycine et de ses dérivés
EP1949844A4 (fr)	2011-10-05	Procede de diagnostic endoscopique ou dispositif therapeutique et medical
EP2101815A4 (fr)	2010-10-06	Procede efficace de traitement du circovirus porcin et des infections par lawsonia intracellularis
EP2219669A4 (fr)	2011-03-09	Compositions et procédés pour le traitement de maladies auto-immunes et allergiques
EP2064319A4 (fr)	2009-12-30	Méthodes de production de cellules gliales et neuronales et leur utilisation pour le traitement de troubles médicaux du système nerveux central
DE602006003973D1 (de)	2009-01-15	Verfahren und Vorrichtung zur Wasserbehandlung
EP2068622A4 (fr)	2012-10-10	Procédé et mélange pour la réticulation photochimique in vivo du collagène
EP2139460A4 (fr)	2011-09-07	Compositions et procédés permettant le diagnostic, le traitement et la prévention de la sclérose latérale amyotrophique et des maladies neurologiques apparentées
EP2504428A4 (fr)	2013-09-25	Procédés et compositions de traitement de maladies liées à l'oxalate
EP2049140A4 (fr)	2012-10-24	Coffret et procédés de traitement d'un disque intervertébral
EP1786332A4 (fr)	2009-10-28	Procede et appareil destines a effectuer des mesures de tension ultrasonores ameliorees des tissus mous

Legal Events

Date	Code	Title	Description
2009-01-30	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2009-03-04	17P	Request for examination filed	Effective date: 20081222
2009-03-04	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR
2009-03-04	AX	Request for extension of the european patent	Extension state: AL BA HR MK RS
2009-05-06	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: THE HOSPITAL FOR SICK CHILDREN Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
2009-07-22	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: THE HOSPITAL FOR SICK CHILDREN Owner name: BETH ISRAEL DEACONESS MEDICAL CENTER
2009-08-14	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1125675 Country of ref document: HK
2010-12-08	A4	Supplementary search report drawn up and despatched	Effective date: 20101109
2011-12-09	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2012-01-11	18D	Application deemed to be withdrawn	Effective date: 20110607
2023-12-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1125675 Country of ref document: HK